Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 780 in its research report dated January 18, 2023.

Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.

Eris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceuticals sector.

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated January 18, 2023.

The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction is expected to achieve financial closure very soon, Eris said

Net Sales are expected to increase by 37 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 4,549 crore, according to Nirmal Bang.

Shares of HCL Technologies dropped sharply in December by more than 7%, after the company trimmed its revenue growth guidance for the current financial year, citing that higher-than-expected furloughs will affect growth in the second half of the year.

“A better way to play pharma would be through hospital stocks. Then we also have these domestic-oriented pharma companies like JB Chemicals or Eris Lifesciences and then the pharma MNCs. Those also are a secular growth story at this point of time because spending on medicine is going to keep on increasing as healthcare possibilities expand.”

“The way Apollo has strategised the capital allocation policy and the value which they are creating in digital business is impressive. I would go with that company. Of course, there are other plays as well but when you like a sector, you go for the market leader and that generally works out pretty well.”

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated October 25, 2022.

It occurs when the short-term moving average crosses over the major long-term moving average on the upside. These stocks' 50-day simple moving averages (SMA) crossed their 200-day SMAs on September 29.

Stocks such as Shree Cement, Wonderla Holidays, Jyothy Labs, Phoenix Mills, Prataap Snacks and Eris Lifesciences are showing bearish trends on the MACD indicator.

Eris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 9395.71 Crore) operating in Pharmaceuticals sector.

Through acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry segments, followed by another acquisition in 2019 of anti-diabetes brand Zomelis, generic version of Vildagliptin, from Novartis, which became a ₹100 crore brand for the company. Earlier this year, the company bought Oaknet for ₹650 crore. Eris Lifesciences ended 2021-22 with revenues of ₹1,347 crore, with 53% contributed by cardiology and anti-diabetes medications.

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 825 in its research report dated August 08, 2022.

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its revenues from cardio-metabolic therapeutic segment, and has adopted a “Full Service” approach to diabetes management with a comprehensive range of oral anti-diabetics, insulins, and glucose testing devices.

Net Sales are expected to increase by 9.1 percent Y-o-Y (up 24.6 percent Q-o-Q) to Rs 381.1 crore, according to Prabhudas Lilladher.

Eris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8921.10 Crore) operating in Pharmaceuticals sector.

“Only three things work in the market; growth, growth and growth. That is all. We are chasing that and at this point of time, growth is available at reasonable valuation. It is a simple mantra one can follow and one cannot go wrong over there. ”

“There is no visibility of a timeline as to when the current crisis around inflation and the Ukraine war will end. There are too many unanswered questions and in such times, it is better to not to have a cowboy attitude and just be on the safer side and take defensive positions and create as much cash as and when you have an opportunity to do so.”

BI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing.

AIA Engineering, Fine Organic, Timken India, CreditAccess Grameen, M&M, Pheonix Mills and HAL witnessed strong buying interest from market participants as they scaled their fresh 52-week highs, signalling bullish sentiment.

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 16, 2022.

Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 05, 2022.

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated May 05, 2022.

The drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly owned subsidiary of Eris.

The acquisition will be completed by way of a share purchase agreement and accordingly Oaknet will become a wholly-owned subsidiary of Eris, the drug firm said in a statement.

On the outlook, Eris Lifesciences said it has an exciting pipeline of 'patent expiration' opportunities coming up in the cardiometabolic segment over the next three to four years.

Net Sales are expected to increase by 12.2 percent Y-o-Y (down 6.1 percent Q-o-Q) to Rs 312.1 crore, according to Prabhudas Lilladher.

Revenue stood at Rs 332 crore in the third quarter of the current fiscal as compared to Rs 310 crore in the year-ago period, Eris Lifesciences said in a statement.

"I am extremely bullish on the economy as the Tsunami of retail investors gives me a lot of confidence that CY2022 is going to be the year of small and midcaps."

Shares of healthcare stocks – pharma companies and diagnostic companies – jumped in trade today as the government got into battle mode to stem the spread of the Omicron variant.